

Pitching to Medtech Investors

David Grimm, Investment Director, UCL Technology Fund










9 years and >500 medtech pitches




Combined Market Cap of largest SW companies* (\$trn)



Log price per (\$) per unit:

- Compute power (GFLOPS
- 1 genome sequence (WGS)



Increased appetite for digital health and medtech investments

+

Large amounts of VC dry powder

More investors investing in the sector

- An investor who understands the journey
 - An experienced medtech investor should be provide constructive challenge
- An investor with a relevant network

- A referenceable approach to adversity
- Patient capital

Pitching is hard

- Medtech pitching is very hard
 - Deep science and technology to explain
 - Market dynamics affected by payors, fragmented markets, clinical needs
 - Each specialism fragmenting the value picture

 Diving into an explanation of the science, or inventiveness of your product without setting the scene.

- Problem should always come first.
- Don't assume high levels of knowledge about the context of the problem
- Whose problem? When does it happen? Why?

- Only explaining one part of a multi stakeholder dynamic
- Why will the patient benefit?

#2 Drivers for adoption

- Why will the physician benefit?
- Why will their institution benefit?
- Why will the payors benefit?
- Why will the channels benefit?

10

Clinical data story focussed only on regulation

Reimbursement story missing

Marketing to physicians missing

 The values achieved for medtech companies are super specific to stages, sectors and technologies

Don't show comparators that aren't relevant

Software ≠ Hardware Cardiology ≠ Endoscopy

Revenue generators ≠ Pre-revenue businesses